LEXX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LEXX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for Lexaria Bioscience's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience Annual Data | |||||||||||||||||||||
Trend | Oct13 | Aug15 | Aug16 | Aug17 | Aug18 | Aug19 | Aug20 | Aug21 | Aug22 | Aug23 | |||||||||||
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Lexaria Bioscience Quarterly Data | ||||||||||||||||||||
May19 | Aug19 | Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | |
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Lexaria Bioscience's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Lexaria Bioscience's E10 for the quarter that ended in Feb. 2024 is calculated as:
For example, Lexaria Bioscience's adjusted earnings per share data for the three months ended in Feb. 2024 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Feb. 2024 (Change) | * | Current CPI (Feb. 2024) |
= | -0.06 | / | 125.4675 | * | 125.4675 | |
= | -0.060 |
Current CPI (Feb. 2024) = 125.4675.
Lexaria Bioscience Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201404 | -0.545 | 98.920 | -0.691 |
201407 | -0.545 | 99.315 | -0.689 |
201411 | -0.273 | 99.078 | -0.346 |
201502 | -0.273 | 99.078 | -0.346 |
201505 | -0.273 | 100.263 | -0.342 |
201508 | -0.109 | 100.579 | -0.136 |
201511 | -0.300 | 100.421 | -0.375 |
201602 | -0.300 | 100.421 | -0.375 |
201605 | -0.300 | 101.765 | -0.370 |
201608 | -0.300 | 101.686 | -0.370 |
201611 | -0.300 | 101.607 | -0.370 |
201702 | -0.300 | 102.476 | -0.367 |
201705 | -0.300 | 103.108 | -0.365 |
201708 | -0.300 | 103.108 | -0.365 |
201711 | -0.300 | 103.740 | -0.363 |
201802 | -0.600 | 104.688 | -0.719 |
201805 | -1.500 | 105.399 | -1.786 |
201808 | -0.300 | 106.031 | -0.355 |
201811 | -0.300 | 105.478 | -0.357 |
201902 | -0.300 | 106.268 | -0.354 |
201905 | -0.300 | 107.927 | -0.349 |
201908 | -0.300 | 108.085 | -0.348 |
201911 | -0.330 | 107.769 | -0.384 |
202002 | -0.380 | 108.559 | -0.439 |
202005 | -0.500 | 107.532 | -0.583 |
202008 | -0.240 | 108.243 | -0.278 |
202011 | -0.240 | 108.796 | -0.277 |
202102 | 0.090 | 109.745 | 0.103 |
202105 | -0.500 | 111.404 | -0.563 |
202108 | -0.240 | 112.668 | -0.267 |
202111 | -0.350 | 113.932 | -0.385 |
202202 | -0.250 | 115.986 | -0.270 |
202205 | -0.410 | 120.016 | -0.429 |
202208 | -0.240 | 120.569 | -0.250 |
202211 | -0.300 | 121.675 | -0.309 |
202302 | -0.220 | 122.070 | -0.226 |
202305 | -0.370 | 124.045 | -0.374 |
202308 | -0.120 | 125.389 | -0.120 |
202311 | -0.130 | 125.468 | -0.130 |
202402 | -0.060 | 125.468 | -0.060 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Lexaria Bioscience (NAS:LEXX) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Lexaria Bioscience's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Catherine C. Turkel | director | 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612 |
Gregory Downey | officer: Chief Financial Officer | 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7 |
Christopher Bunka | director, 10 percent owner, officer: CEO | 1924 BIRKDALE AVE, KELOWNA A1 V1P1R7 |
Vanessa Carle | officer: Secretary | 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7 |
Reese Albert L Jr | director | |
Brian W. Quigley | director | 100 740 MCCURDY ROAD, KELOWNA A1 23230 |
William Edward Mckechnie | director | 305 MARGARET AVENUE, KITCHENER A6 N2H 6S4 |
Allan Horst Spissinger | officer: CFO | 8131 198A STREET, LANGLEY A1 V2Y 1Y6 |
John Martin Docherty | director, 10 percent owner | 23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1 |
Baljinder Bhullar | director, officer: CFO | 604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8 |
Nicholas W Baxter | director | 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU |
Dustin Arthur Elford | director | 888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4 |
Thomas James Ihrke | officer: Sr. VP, Business Development | 38 KRIER LANE, MOUNT PLEASANT SC 29464 |
David Demartini | director, 10 percent owner | 11714 SPRIGGS WAY, HOUSTON TX 77024 |
Leonard Macmillan | director, officer: Vice President - Corp Develop | SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 05-11-2023
By ACCESSWIRE • 06-22-2023
By ACCESSWIRE • 10-13-2023
By ACCESSWIRE • 07-19-2023
By ACCESSWIRE ACCESSWIRE • 05-08-2023
By ACCESSWIRE ACCESSWIRE • 03-02-2023
By ACCESSWIRE • 01-16-2024
By ACCESSWIRE • 09-21-2023
By ACCESSWIRE • 09-29-2023
By ACCESSWIRE • 08-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.